The verdict
Our read at a glance.
Whether a drug approved to restore weight after trauma, surgery or infection is mild enough to be treated casually.
- The signal
- This is the strongest clinical file in the class. Oxandrolone has an approved indication as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infection or severe trauma, and in some patients who fail to gain or maintain weight without a defined cause. The evidence in severe burns is substantial and sustained, with a long trial literature examining lean mass, donor site healing and recovery in burned patients including children. Registered trials continue in defined clinical settings. That is a real, specific, and narrow evidence base.
- The unknown
- Whether the burns and catabolic-state data generalise at all to healthy people using it for physique, which has never been the subject of a comparable trial, and what repeated cycles do to lipids over years.
- Our read
- The most defensible drug in the class on evidence, and the one most misrepresented in practice. Approved for burns and catabolic weight loss on real data. Called mild because it does not make you look bloated, while doing more damage to HDL than the compounds it is compared favourably against.
The mechanism
How it works.
Oxandrolone is a dihydrotestosterone derivative modified in two ways. An oxygen atom replaces a carbon in the A ring, and a methyl group is added at the 17-alpha position. The 17-alpha methylation is what lets it survive first-pass metabolism in the liver and work as an oral, and it is also the structural feature responsible for the class's hepatic effects and for the characteristic suppression of HDL cholesterol, which happens through induction of hepatic lipase. Because it derives from dihydrotestosterone it is not a substrate for aromatase and produces no oestradiol. In a catabolic patient the effect on nitrogen balance is the therapeutic point: it shifts protein metabolism toward synthesis at a time when the body is breaking tissue down, which is why the burns literature is where its evidence is strongest.
Safety & regulatory boundary
The consequential part.
Approved for specific catabolic indications, not for physique or performance, and a Schedule III controlled substance. The reputation for mildness is misleading in one specific and important way: as a 17-alpha-alkylated oral it suppresses HDL cholesterol severely, often more than injectable androgens do, and that effect is dose-related and reliable rather than idiosyncratic. It is still hepatotoxic, still suppresses the gonadal axis, and in women is virilising at sufficient exposure. Prohibited in sport.
What's next
What we're watching.
Continued burns and catabolic-state trials, and any data on lipid recovery after repeated exposure.
Context
Why this is discussed.
It is the standard recommendation for people who want an oral steroid without the obvious hepatotoxicity of the 1970s compounds, and it is the one most often described as safe enough for women and for first cycles.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · TERMINATED · 2018-09-23
ClinicalTrials.gov · PHASE4 · SUSPENDED · 2023-07-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-11-28
ClinicalTrials.gov · PHASE1/PHASE2 · TERMINATED · 2019-12-20
ClinicalTrials.gov · PHASE2 · RECRUITING · 2023-07-21
ClinicalTrials.gov · PHASE3 · WITHDRAWN · 2022-05-19
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2000-07
ClinicalTrials.gov · PHASE3 · COMPLETED · 2004-03-01
Indexed literature (PubMed)12
Akyurek M et al. · Plast Reconstr Surg · 2006
Kopel J et al. · J Pharm Technol · 2022
Ring J et al. · J Burn Care Res · 2020
Jalkh APC et al. · Cureus · 2022
Mohamed S et al. · Cochrane Database Syst Rev · 2019
Lou J et al. · World J Emerg Surg · 2025
Knuth CM et al. · Am J Physiol Cell Physiol · 2021
Real DS et al. · Acta Cir Bras · 2014
Miller JT et al. · Pharmacotherapy · 2009
Miller JT et al. · Ann Pharmacother · 2008
Berger JR et al. · AIDS · 1996
Péret LA et al. · J Vasc Bras · 2019
Keep reading